{"symbol":"LLY","fiscalQuarter":"Q1-2026","reportDate":"2026-04-30","reportTime":"BMO","status":"reported","company":{"name":"Eli Lilly and Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/LLY/earnings/Q1-2026","estimates":{"consensusEps":6.8379,"consensusRevenue":17840,"epsLow":3.11,"epsHigh":7.77,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Eli Lilly and Company (LLY) is a leading pharmaceutical company that develops and manufactures medications for various health conditions, including diabetes and cancer. With a market cap of $764 billion, it plays a significant role in the healthcare sector, focusing on innovative treatments that address unmet medical needs.","keyMetrics":[{"name":"EPS","why":"Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.","consensus":"$6.84"},{"name":"Revenue","why":"Total revenue reflects the company's sales performance and growth potential, which is crucial for understanding market demand for its products.","consensus":"$17.8B"}],"lastQuarterRecap":{"summary":"In the last quarter, Eli Lilly reported an EPS of $7.54, exceeding estimates by 7.88%, which positively impacted the stock price. However, revenue figures were not disclosed, leaving some uncertainty about overall sales performance.","promises":["Focus on expanding its diabetes and cancer treatment portfolios.","Commitment to maintaining strong research and development efforts.","Plans to enhance global market access for its key products."]},"wallStreetExpectations":{"summary":"Analysts expect Eli Lilly to report strong earnings driven by its innovative drug portfolio, with a consensus EPS of $6.84. However, there are concerns about potential pricing pressures and competition in the pharmaceutical market.","bullCase":"If Eli Lilly beats EPS expectations and shows robust revenue growth, it could signal strong demand for its products, leading to a positive stock reaction.","bearCase":"If the company misses EPS estimates or provides weak guidance, it could raise concerns about its growth trajectory and lead to a negative market response."},"optionsSignal":{"impliedMove":"6.42%","context":"The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement."},"earningsTrackRecord":[{"quarter":"Q4-2025","epsSurprise":"+7.88%","reaction":"+10.33%"},{"quarter":"Q3-2025","epsSurprise":"+16.59%","reaction":"+3.81%"},{"quarter":"Q2-2025","epsSurprise":"+14.08%","reaction":"-14.14%"},{"quarter":"Q1-2025","epsSurprise":"-5.01%","reaction":"-11.66%"}],"pivotalQuestions":[{"question":"Will Eli Lilly's EPS exceed the consensus estimate of $6.84?","whyItMatters":"A beat on EPS could indicate strong operational performance and boost investor confidence."},{"question":"What guidance will management provide for future revenue growth?","whyItMatters":"Management's outlook on revenue growth will be critical for assessing the company's ability to sustain its momentum."}],"thesisBreakLevels":{"bullTrigger":"Eli Lilly must report an EPS above $7.00 and provide strong revenue guidance to confirm the bull case.","bearTrigger":"An EPS below $6.50 or weak revenue guidance would support the bear case.","context":"Investors are closely watching how the company balances growth with potential pricing pressures in the pharmaceutical market."},"scenarioPlaybook":{"beatAndRaise":"If Eli Lilly beats expectations, history suggests a potential stock increase of around +3.13%, confirming strong demand for its products.","inLineCautious":"If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.","miss":"Should the company miss earnings expectations, history suggests a potential decline of around -8.97%, raising concerns about future growth."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating the impact of Eli Lilly's recent product launches, which could drive higher-than-expected sales.","supportingPoints":["The company has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.","Options are pricing a 6.42% move, but the stock has historically moved more than that, suggesting potential for a larger reaction."],"riskToConsensus":"If the company reports strong sales growth in its key therapeutic areas, it could challenge the current consensus."},"whatToListenFor":["Updates on the performance of diabetes and cancer drugs.","Any commentary on pricing strategies and market competition.","Insights into research and development progress for new treatments.","Management's outlook on global market expansion efforts.","Details on cost management and operational efficiencies."],"metaDescription":"Eli Lilly (LLY) reports Q1 2026 earnings April 30. Analysts expect $6.84 EPS on $17.8B revenue. Here's what to watch."},"postBrief":{"headline":"Eli Lilly Beats on EPS, Stock Up 9.8%","keyNumbers":[{"metric":"EPS","actual":"$8.55","expected":"$6.84","surprise":"+21.07%"},{"metric":"Revenue","actual":"N/A","expected":"$17.8B","surprise":"N/A"}],"managementCommentary":{"tone":"Unknown","keyQuotes":[],"summary":"No transcript is on record, and the analysis is based on numerical results only."},"guidanceChanges":{"summary":"No forward guidance data is available.","changes":[]},"whatItMeans":"Eli Lilly's strong earnings per share of $8.55 significantly exceeded expectations, contributing to a 9.8% rise in stock price. The positive surprise in EPS indicates robust performance, although revenue figures were not disclosed. Investors may view this as a sign of the company's strong operational efficiency and potential growth.","metaDescription":"Eli Lilly (LLY) Q1 2026 earnings: EPS beat by 21.07%. Stock up 9.8%. Full breakdown."}}